Reviewing Oncomed Pharmaceuticals (OMED) & Its Rivals
Oncomed Pharmaceuticals (NASDAQ: OMED) is one of 190 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Oncomed Pharmaceuticals to related businesses based on the strength of its earnings, valuation, institutional ownership, dividends, profitability, risk and analyst recommendations.
This table compares Oncomed Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Oncomed Pharmaceuticals Competitors||-4,483.25%||-554.35%||-42.95%|
This table compares Oncomed Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Oncomed Pharmaceuticals||$25.15 million||-$103.10 million||-2.10|
|Oncomed Pharmaceuticals Competitors||$217.29 million||-$39.39 million||-61.40|
Oncomed Pharmaceuticals’ rivals have higher revenue and earnings than Oncomed Pharmaceuticals. Oncomed Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Oncomed Pharmaceuticals has a beta of 2.8, meaning that its share price is 180% more volatile than the S&P 500. Comparatively, Oncomed Pharmaceuticals’ rivals have a beta of 1.55, meaning that their average share price is 55% more volatile than the S&P 500.
Insider and Institutional Ownership
39.4% of Oncomed Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 32.8% of Oncomed Pharmaceuticals shares are owned by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of current ratings and price targets for Oncomed Pharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Oncomed Pharmaceuticals Competitors||543||2475||6714||128||2.65|
Oncomed Pharmaceuticals presently has a consensus price target of $6.00, suggesting a potential upside of 51.13%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.46%. Given Oncomed Pharmaceuticals’ higher probable upside, equities analysts plainly believe Oncomed Pharmaceuticals is more favorable than its rivals.
Oncomed Pharmaceuticals rivals beat Oncomed Pharmaceuticals on 7 of the 12 factors compared.
About Oncomed Pharmaceuticals
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.